Scholarlink

Purpose <p>Migraine, a prevalent neurological condition, necessitates innovative treatments beyond existing symptomatic remedies. Drug repurposing presents a fast-track solution, with naloxone identified as a candidate for migraine therapy, despite challenges such as limited blood-brain barrier permeability, short half-life, and extensive hepatic metabolism. However, the therapeutic potential of naloxone can be enhanced through lipid-drug conjugation technique, which improves lipophilicity, optimizes pharmacokinetic parameters, and bypasses hepatic metabolism by facilitating lymphatic targeting when taken orally, allowing extended therapeutic effects.</p> Methods <p>The present investigation employed in silico methods to study naloxone and its lipid conjugates, focusing on their modified physicochemical, pharmacokinetic, and pharmacodynamic characteristics. The investigation integrated computational ADMET assessments, therapeutic target forecasting, and molecular docking simulations to validate the interactions of naloxone and its lipid-based derivatives with <i>serotonin, toll-like,</i> and <i>μ-opioid</i> receptors using SwissADME, PKCSM (Deep-PK), Protox, SwissTarget, and SwissDock, respectively.</p> Results <p>The results revealed that lipid conjugation significantly modified the physicochemical and pharmacokinetic profiles of naloxone by increasing its half-life, decreasing volume of distribution, altering metabolic profile, and decreasing clearance rate. Target prediction profile of drug and its conjugates revealed its neuroprotective, anti-inflammatory, vasomodulatory, immunomodulatory, analgesic, antidepressant activity. The binding affinity for <i>serotonin, toll-like,</i> and <i>μ-opioid</i> receptors demonstrated its effectiveness for migraine treatment, including pain modulation, neuroinflammation, and serotonergic dysregulation.</p> Conclusion <p>In silico predictions suggest that naloxone and its lipid conjugates are promising candidates for migraine treatment. This approach has potential for the design of novel, brain-targeted, and serotonin-modulating compounds for migraine treatment following in vitro and in vivo validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In Silico Evaluation of Lipid-Drug Conjugates: Pharmacokinetic and Pharmacodynamic Profiling for Therapeutic Repurposing of Naloxone in Migraine Management

  • 期刊论文

  • 发表日期：

    2026年1月27日

查看全文
  • Ami Patel,
  • Amit Dabke,
  • Krutika Sawant

摘要

Purpose

Migraine, a prevalent neurological condition, necessitates innovative treatments beyond existing symptomatic remedies. Drug repurposing presents a fast-track solution, with naloxone identified as a candidate for migraine therapy, despite challenges such as limited blood-brain barrier permeability, short half-life, and extensive hepatic metabolism. However, the therapeutic potential of naloxone can be enhanced through lipid-drug conjugation technique, which improves lipophilicity, optimizes pharmacokinetic parameters, and bypasses hepatic metabolism by facilitating lymphatic targeting when taken orally, allowing extended therapeutic effects.

Methods

The present investigation employed in silico methods to study naloxone and its lipid conjugates, focusing on their modified physicochemical, pharmacokinetic, and pharmacodynamic characteristics. The investigation integrated computational ADMET assessments, therapeutic target forecasting, and molecular docking simulations to validate the interactions of naloxone and its lipid-based derivatives with serotonin, toll-like, and μ-opioid receptors using SwissADME, PKCSM (Deep-PK), Protox, SwissTarget, and SwissDock, respectively.

Results

The results revealed that lipid conjugation significantly modified the physicochemical and pharmacokinetic profiles of naloxone by increasing its half-life, decreasing volume of distribution, altering metabolic profile, and decreasing clearance rate. Target prediction profile of drug and its conjugates revealed its neuroprotective, anti-inflammatory, vasomodulatory, immunomodulatory, analgesic, antidepressant activity. The binding affinity for serotonin, toll-like, and μ-opioid receptors demonstrated its effectiveness for migraine treatment, including pain modulation, neuroinflammation, and serotonergic dysregulation.

Conclusion

In silico predictions suggest that naloxone and its lipid conjugates are promising candidates for migraine treatment. This approach has potential for the design of novel, brain-targeted, and serotonin-modulating compounds for migraine treatment following in vitro and in vivo validation.